Brain 17 Vienna

PROFILE trials 1005 & 1007

ALK+ advanced NSCLC & brain metastases

brain mets previously untreated

no brain mets

no. pts

166

613

PFS median

5.9m (4.2-6.9) 77% (67-85)

8.8m (7.9-9.9) 85% (81-87)

6 m OS

613 patients

275 patients

Brain metastases in patients with ALK-positive NSCLC

Costa et al 2015, J Clin Oncol; 33 (17): 1881-1888